Latest Regulatory Clearance News

Page 6 of 38
Arovella Therapeutics has released the first clinical batch of its off-the-shelf cell therapy ALA-101 and activated its inaugural trial site at The Alfred, setting the stage for patient dosing later this month.
Ada Torres
Ada Torres
7 Sept 2026
Alcoa Corporation has filed to register shares of its common stock to be issued in connection with its $4.1 billion acquisition of South32 Limited’s upstream aluminum assets, spanning Australia, Brazil and South Africa. The deal includes cash, stock consideration, and contingent payments linked to commodity prices, pending customary approvals and shareholder support.
Maxwell Dee
Maxwell Dee
2 Sept 2026
CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.
Ada Torres
Ada Torres
31 Aug 2026
Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.
Victor Sage
Victor Sage
31 Aug 2026
Heartland has cleared a major hurdle in its $620 million acquisition of TSB, with Toi Foundation trustees approving the sale. The merger aims to create a stronger regional challenger bank, pending shareholder and regulatory green lights.
Claire Turing
Claire Turing
27 Aug 2026
Acrow Limited secures final ACCC approval for its AusGroup Industrial Services acquisition, clearing the path for completion on 1 September 2026 and strengthening its foothold in Australia’s civil infrastructure sector.
Victor Sage
Victor Sage
26 Aug 2026
Ingenia Communities Group proposes to acquire Peet Limited via a scheme of arrangement, forming a leading national living sector platform with a $1 billion land lease conversion opportunity and expected low double-digit EPS accretion.
Eva Park
Eva Park
26 Aug 2026
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
Ada Torres
Ada Torres
25 Aug 2026
Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.
Ada Torres
Ada Torres
25 Aug 2026
Scentre Group has sold half ownership of Westfield Mt Gravatt to Australian Retirement Trust for $882.5 million, marking a strategic joint venture and a 3.5% premium to book value.
Eva Park
Eva Park
24 Aug 2026
EMVision Medical Devices has made significant strides in its emu™ bedside scanner pivotal trial and First Responder program, boosting FY26 revenue by 57% while trimming its net loss by 15%.
Ada Torres
Ada Torres
24 Aug 2026
EQT Holdings has received a non-binding takeover proposal from BGH Capital valuing the company at $24.75 per share, subject to due diligence and regulatory approvals.
Claire Turing
Claire Turing
21 Aug 2026

Browse the archive

Full archive